Pursuant to Regulation 110 of the Companies Act, 2013 read with Companies (Management and Administration) Rules, 2014, Caplin Point Laboratories has informed that the approval of the Members of the company was sought for the Special resolution of transfer of business undertaking of the company (Regulated Markets injectable Business, including USFDA approved injectable plant and DSIR recognized R&D units CP4 & CP5) to its Wholly Owned Subsidiary company, by means of Postal Ballot including e-voting vide Postal Ballot Notice dated November 19, 2018. The details of combined voting results (e-voting and voting through Postal Ballot Forms) and report of the Scrutinizer are enclosed as Annexures.
The above information is a part of company’s filings submitted to BSE.
